A Bifunctional Lysosome‐Targeting Chimera Nanoplatform for Tumor‐Selective Protein Degradation and Enhanced Cancer Immunotherapy
Advanced Materials · 2025-03 · 37 (10)
DOI: 10.1002/adma.202417942 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 31.01.2025. Verfasst von Yumeng Xing und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230032, China. Hauptthemen laut MEDLINE: Lysosomes, Immunotherapy, Nanoparticles, Neoplasms. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Research Project for Anhui Universities, Natural Science Foundation of Anhui Province.
Abstract (Originalsprache)
Lysosome‐targeting chimeras (LYTACs) have recently emerged as a promising therapeutic strategy for degrading extracellular and membrane‐associated pathogenic proteins by hijacking lysosome‐targeting receptors. However, the antitumor performance of LYTAC is limited by its insufficient tumor accumulation and nonspecific activation. Additionally, the synergistic effects of LYTACs and other therapeutic modalities are crucial. To address these issues, a bifunctional LYTAC nanoplatform (NLTC) is developed for tumor‐selective protein degradation and enhanced cancer immunotherapy. By rationally controlling the surface composition, the NLTC can effectively transport extracellular or membrane proteins into lysosomes for degradation via cation‐independent mannose 6‐phosphate receptors. With removable surface modification, an NLTC is obtained that efficiently accumulated in tumor tissues and avoided on‐target off‐tumor toxicity. Moreover, the synthesis method of NLTC is generally applicable to various enzymes. Thus, catalase (CAT) is encapsulated with NLTC to synergistically degrade cancer cell surface programmed death ligand‐1 (PD‐L1), relieve the immunosuppressive tumor microenvironment for effective cancer immunotherapy, and significantly inhibit tumor growth, recurrence, and metastasis in B16F10‐bearing mice. This work presents a bifunctional LYTAC nanoplatform that can not only perform tissue‐selective protein degradation but also integrate other therapeutic modalities, providing insights into the design of advanced LYTAC technologies for clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230032, China.
- School of Pharmacy, Inflammation and Immune-Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei, 230032, China.
- College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, China.
- Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230032, China.
- College of Chemistry, Nankai University, Tianjin, 300071, China.
ORCID-Profile: Qi Liu
Förderung
- National Natural Science Foundation of China
- Natural Science Research Project for Anhui Universities
- Natural Science Foundation of Anhui Province
- Pharmacy Peak Discipline Talent Support Project of Anhui Medical University
- Research Fund of Anhui Institute of translational medicine
Zitieren
APA
Xing, Y., Li, J., Wang, L., Zhu, Z., Yan, J., Liu, Y., & Liu, Q. (2025). A Bifunctional Lysosome‐Targeting Chimera Nanoplatform for Tumor‐Selective Protein Degradation and Enhanced Cancer Immunotherapy. Advanced Materials, 37(10). https://doi.org/10.1002/adma.202417942
Vancouver
Xing Y, Li J, Wang L, Zhu Z, Yan J, Liu Y, et al. A Bifunctional Lysosome‐Targeting Chimera Nanoplatform for Tumor‐Selective Protein Degradation and Enhanced Cancer Immunotherapy. Advanced Materials. 2025;37(10). doi:10.1002/adma.202417942
BibTeX
@article{Xing2025,
author = {Xing, Yumeng and Li, Jingjing and Wang, Leyuan and Zhu, Zhihui and Yan, Jian and Liu, Yang and Liu, Qi},
title = {A Bifunctional Lysosome‐Targeting Chimera Nanoplatform for Tumor‐Selective Protein Degradation and Enhanced Cancer Immunotherapy},
journal = {Advanced Materials},
year = {2025},
volume = {37},
number = {10},
doi = {10.1002/adma.202417942}
}
EUVIMED